PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer

被引：0
|
作者：
Antonia, S. J. [1 ]
Villegas, A. [2 ]
Daniel, D. [3 ,4 ]
Baz, D. Vincente [5 ]
Murakami, S. [6 ]
Hui, R. [7 ,8 ]
Yokoi, T. [9 ]
Chiappori, A. [1 ]
Lee, K. H. [10 ]
de Wit, M. [11 ]
Cho, B. C. [12 ]
Bourhaba, M. [13 ]
Quantin, X. [14 ,15 ]
Tokito, T. [16 ]
Mekhail, T. [17 ]
Planchard, D. [18 ]
Jiang, H. [19 ]
Huang, Y. [19 ]
Dennis, P. A. [19 ]
Ozguroglu, M. [20 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Canc Specialists North Florida, Jacksonville, FL USA
[3] Tennessee Oncol, Chattanooga, TN USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Hosp Univ Virgen Macarena, Seville, Spain
[6] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[7] Westmead Hosp, Sydney, NSW, Australia
[8] Univ Sydney, Sydney, NSW, Australia
[9] Kansai Med Univ Hosp, Hirakata, Osaka, Japan
[10] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea
[11] Vivantes Klinikum Neukoelln, Berlin, Germany
[12] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[13] Ctr Hosp Univ Liege, Liege, Belgium
[14] CHU Montpellier, Montpellier, France
[15] ICM Val dAurelle, Montpellier, France
[16] Kurume Univ Hosp, Kurume, Fukuoka, Japan
[17] Florida Hosp, Inst Canc, Orlando, FL USA
[18] Gustave Roussy, Villejuif, France
[19] AstraZeneca, Gaithersburg, MD USA
[20] Istanbul Univ, Cerrahpasa Med Sch, Istanbul, Turkey
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2017年 / 99卷 / 05期
关键词：
D O I：
10.1016/j.ijrobp.2017.09.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA-4
引用
收藏
页码：1314 / 1315
页数：4
相关论文
共 50 条
  • [41] A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY OF MEDI4736 IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE NSCLC (STAGE III) WHO HAVE NOT PROGRESSED FOLLOWING PLATINUM-BASED, CONCURRENT CHEMORADIATION THERAPY (PACIFIC)
    Antonia, S.
    Iannotti, N. O.
    Salamat, M. A.
    Krebs, A. D.
    Jayawardene, D.
    Ballas, M.
    Stockman, P. K.
    ANNALS OF ONCOLOGY, 2014, 25
  • [42] Efficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study
    Nishibori, Yuichiro
    Kenmotsu, Hirotsugu
    Ando, Kenju
    Tonsho, Ayumi
    Matsuda, Suguru
    Morita, Meiko
    Sekikawa, Motoki
    Doshita, Kosei
    Morikawa, Noboru
    Miura, Keita
    Kodama, Hiroaki
    Yabe, Michitoshi
    Iida, Yuko
    Mamesaya, Nobuaki
    Kobayashi, Haruki
    Ko, Ryo
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Harada, Hideyuki
    Takahashi, Toshiaki
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 41
  • [43] First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
    Lee, Siow Ming
    Khan, Iftekhar
    Upadhyay, Sunil
    Lewanski, Conrad
    Falk, Stephen
    Skailes, Geraldine
    Marshall, Ernie
    Woll, Penella J.
    Hatton, Matthew
    Lal, Rohit
    Jones, Richard
    Toy, Elizabeth
    Chao, David
    Middleton, Gary
    Bulley, Sue
    Ngai, Yenting
    Rudd, Robin
    Hackshaw, Allan
    Boshoff, Chris
    LANCET ONCOLOGY, 2012, 13 (11): : 1161 - 1170
  • [44] Association of the Benefit of Durvalumab Consolidation Therapy and Driver Mutation Status for Locally Advanced Non-small Lung Cancer
    Akazawa, Y.
    Yoshikawa, A.
    Miyamoto, S.
    Ameku, K.
    Yano, Y.
    Mori, M.
    Uchida, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S574 - S575
  • [45] Phase II/III clinical trial of randomized, double-blind, placebo-controlled combined with recombinant human endostatin in treatment of advanced non-small cell lung cancer
    Xu Liyan
    Shi He Heling
    Liu Zhe
    Zhu Yunzhong
    Li Baolan
    Zhang Shucai
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S354 - S354
  • [46] A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naive metastatic/unresectable non-small cell lung cancer
    Reck, Martin
    Krzakowski, Maciej
    Chmielowska, Ewa
    Sebastian, Martin
    Hadler, Dietrich
    Fox, Tara
    Wang, Qiang
    Greenberg, Jon
    Beckman, Robert A.
    von Pawel, Joachim
    LUNG CANCER, 2013, 82 (03) : 441 - 448
  • [47] Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab
    Diamond, Brett H.
    Belani, Neel
    Masel, Rebecca
    DeCarli, Kathryn
    DiPetrillo, Thomas
    Hepel, Jaroslaw T.
    Azzoli, Christopher G.
    Khurshid, Humera
    Abbas, Abbas
    Koffer, Paul P.
    ADVANCES IN RADIATION ONCOLOGY, 2023, 8 (02)
  • [48] Durvalumab Consolidation Treatment after Chemoradiotherapy for an HIV-Positive Patient with Locally Advanced Non-Small Cell Lung Cancer
    Kawai, Shoko
    Suzuki, Hiroe
    Okuma, Yusuke
    CASE REPORTS IN ONCOLOGY, 2020, 13 (02): : 747 - 753
  • [49] ECONOMIC EVALUATION OF DURVALUMAB FOR THE TREATMENT OF PATIENTS WITH STAGE III UNRESECTABLE LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER PLATINUM-BASED CHEMORADIATION THERAPY
    Rubio Ponce, R.
    Naranjo, M.
    VALUE IN HEALTH, 2022, 25 (12) : S71 - S71
  • [50] Real-World Experience of Consolidation Durvalumab for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
    Barbaro, A.
    Mienko, F.
    Deng, L.
    Ohri, N.
    Halmos, B.
    Perez-Soler, R.
    Gucalp, R.
    Bodner, W.
    Cheng, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S906 - S907
12345